Argenx gears up to launch Vyvgart in next potential indication
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00...
Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam,...
Less than one month after reporting a trial fail for Vyvgart Hytrulo in a rare bleeding disorder, argenx has swung and missed in a group of chronic blistering diseases.
ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indicationUpdate on BALLAD study GO/NO GO decisionConference call scheduled for today, December 20,...
Argenx`s Biologic Vyvgart (efgartigimod) Receives Approval in the U.S.
Argenx`s Biologic Vyvgart Hytrulo (efgartigimod) Receives Approval in the U.S.
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
On a roll with Vyvgart—which is on its way to blockbuster sales in just its second year on the market for generalized myasthenia gravis (gMG)—argenx’s heat check in another indication has missed badly.